“The result is surprising,” Ruth Ruprecht, who directs the AIDS Research Program at Texas Biomedical Research Institute and was not involved in the study, told The Verge. “I am astonished by how long protection lasted.”
“A caveat is that monkeys are not humans, but the model the authors use is about as good as it gets, and the results are a boost to HIV vaccine research and the use of passive antibodies as long-acting preventives,” Scripps Research Institute immunologist Dennis Burton, who was not involved with the work, told Nature. Moreover, added study coauthor Malcolm Martin of NIAID, “this might turn out to be a seasonal alternative to a vaccine until we really know how to make one.”
Such antibody treatments could also one day serve as an alternative to the daily pills of the pre-exposure prophylaxis (PrEP) administered to at-risk individuals today. “PrEP is good if people take it, but we all know that human nature is such that we’re not perfect. We forget things,” Ruprecht told The Verge.
As antibody levels in the monkeys’ blood declined, the animals’ probability of infection following exposure increased. Martin’s team is now working to tweak one of the antibodies so that it will last in the body for a longer period of time. Another way to boost the treatment’s efficacy might be to use a combination of antibodies, the researchers proposed.
“With the extraordinary progress that’s been made just in the past six years, I’m more optimistic than ever that the field will eventually succeed in having an effective prevention measure,” David Montefiori, the director of the Laboratory for AIDS Vaccine Research and Development at Duke University who was not involved in the research, told The Verge. “Hopefully, we’ll see the light at the end of the tunnel within the next 10 years.”